Bank of New York Mellon
KYNB

Bank of New York Mellon’s Kyntra Bio KYNB Stock Holding History

Bank of New York Mellon’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,921
Closed -$700K – 4180
2024
Q1 		$700K Sell
11,921
-562
-5% -$24.2K ﹤0.01% 3333
2023
Q4 		$277K Sell
12,483
-16
-0.1% -$241 ﹤0.01% 3832
2023
Q3 		$270K Sell
12,499
-448
-3% -$17.6K ﹤0.01% 3856
2023
Q2 		$874K Buy
12,947
+1,506
+13% +$623K ﹤0.01% 3282
2023
Q1 		$5.34M Sell
11,441
-369
-3% -$195K ﹤0.01% 2264
2022
Q4 		$4.73M Sell
11,810
-145
-1% -$55.5K ﹤0.01% 2371
2022
Q3 		$3.89M Buy
11,955
+1,222
+11% +$394K ﹤0.01% 2432
2022
Q2 		$2.83M Sell
10,733
-501
-4% -$128K ﹤0.01% 2639
2022
Q1 		$3.38M Buy
11,234
+120
+1% +$41.8K ﹤0.01% 2641
2021
Q4 		$3.92M Sell
11,114
-3,044
-22% -$948K ﹤0.01% 2597
2021
Q3 		$3.62M Sell
14,158
-71,259
-83% -$25.2M ﹤0.01% 2651
2021
Q2 		$56.9M Sell
85,417
-7,859
-8% -$4.53M 0.01% 1056
2021
Q1 		$80.9M Buy
93,276
+21,783
+30% +$23.2M 0.02% 817
2020
Q4 		$66.3M Buy
71,493
+7,281
+11% +$7.65M 0.01% 882
2020
Q3 		$66M Buy
64,212
+3,765
+6% +$4.05M 0.02% 754
2020
Q2 		$61.2M Buy
60,447
+16,410
+37% +$15.2M 0.02% 772
2020
Q1 		$38.3M Sell
44,037
-1,676
-4% -$1.67M 0.01% 903
2019
Q4 		$49M Buy
45,713
+8,040
+21% +$8.21M 0.01% 999
2019
Q3 		$34.8M Sell
37,673
-157
-0.4% -$172K 0.01% 1171
2019
Q2 		$42.7M Buy
37,830
+6,061
+19% +$6.63M 0.01% 1068
2019
Q1 		$43.2M Buy
31,769
+8,053
+34% +$10.9M 0.01% 1049
2018
Q4 		$27.4M Buy
23,716
+10,301
+77% +$11.6M 0.01% 1271
2018
Q3 		$20.4M Sell
13,415
-84
-0.6% -$129K 0.01% 1610
2018
Q2 		$21.1M Sell
13,499
-166
-1% -$216K 0.01% 1570
2018
Q1 		$15.8M Buy
13,665
+341
+3% +$449K ﹤0.01% 1728
2017
Q4 		$15.8M Sell
13,324
-1,460
-10% -$1.83M ﹤0.01% 1728
2017
Q3 		$19.9M Buy
14,784
+3,079
+26% +$3.24M 0.01% 1559
2017
Q2 		$9.45M Buy
11,705
+1,939
+20% +$1.35M ﹤0.01% 2001
2017
Q1 		$6.02M Buy
9,766
+346
+4% +$211K ﹤0.01% 2236
2016
Q4 		$5.04M Buy
9,420
+354
+4% +$177K ﹤0.01% 2304
2016
Q3 		$4.69M Buy
9,066
+17
+0.2% +$8.01K ﹤0.01% 2268
2016
Q2 		$3.71M Sell
9,049
-898
-9% -$411K ﹤0.01% 2363
2016
Q1 		$5.29M Sell
9,947
-339
-3% -$169K ﹤0.01% 2159
2015
Q4 		$7.84M Buy
10,286
+519
+5% +$344K ﹤0.01% 1974
2015
Q3 		$5.35M Buy
9,767
+3,216
+49% +$1.95M ﹤0.01% 2196
2015
Q2 		$3.85M Buy
6,551
+5,023
+329% +$2.92M ﹤0.01% 2528
2015
Q1 		$1.2M Buy
1,528
+282
+23% +$219K ﹤0.01% 3196
2014
Q4 		$851K Buy
+1,246
New +$802K ﹤0.01% 3393

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Bank of New York Mellon's KYNB Position: Q2 2024 in Review

Bank of New York Mellon sold out of Kyntra Bio (KYNB) in Q2 2024, closing a stake of 11,921 shares — an estimated $700K sold.

Bank of New York Mellon first reported a position in KYNB in Q4 2014 and held it in 38 quarters. The position peaked at $80.9M in Q1 2021. 102 funds tracked by Wall St. Rank hold KYNB as of Q2 2024.

  • Bank of New York Mellon reported no remaining Kyntra Bio position as of Q2 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 11,921 Kyntra Bio shares in Q2 2024, an estimated $700K.
  • Bank of New York Mellon first reported a position in Kyntra Bio in Q4 2014 and held it in 38 quarters.
  • Bank of New York Mellon's Kyntra Bio position peaked at $80.9M in Q1 2021.
  • 102 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2024.

Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.